New antibody combo takes on advanced solid tumors

NCT ID NCT06819735

Recruiting now Disease control Sponsor: Domain Therapeutics Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an early-stage trial, so results will guide further research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DT-7012 (an anti-CCR8 antibody) and an immune checkpoint inhibitor
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects, including immune-related reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cabrini Health Limited
RECRUITING

Malvern, Victoria, 3144, Australia
Cancer Research SA
RECRUITING

Adelaide, South Australia, 5000, Australia
Honor Health Research Institute
NOT_YET_RECRUITING

Scottsdale, Arizona, 85258, United States
Hôpitaux Universitaires de Strasbourg
RECRUITING

Strasbourg, 67200, France
Institut Bergonié
RECRUITING

Bordeaux, 33076, France
Institut Gustave Roussy
RECRUITING

Villejuif, 94800, France
Macquarie University Clinical Trial Unit
RECRUITING

North Ryde, New South Wales, 2109, Australia
One Clinical Research Pty Ltd
RECRUITING

Nedlands, Western Australia, 6009, Australia
Peninsula & South Eastern Haematology & Oncology Group
RECRUITING

Frankston, Victoria, 3199, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.